DDInter996 DDInter1676
Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ivabradine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Ivabradine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Ivabradine {u} may lead to a major life threatening interaction when taken with {v} Panobinostat
Ivabradine {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Ivabradine may lead to a major life threatening interaction when taken with Panobinostat
Ivabradine may lead to a major life threatening interaction when taken with Ribociclib